Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Upgrades Kodiak Sciences Inc. (KOD) to Buy
-
Hyperion DeFi completes $10 million public stock offering
-
Hyperion DeFi prices $10 million public stock offering at $3.60 per share
-
Hyperion DeFi announces proposed public offering of stock and warrants
-
Chardan Starts Climb Bio (CLYM) at Buy
-
Intellia Therapeutics (NTLA) PT Raised to $30 at Chardan
-
Chardan Starts Galaxy Digital (GLXY) at Buy
-
Chardan Starts Riot Platforms (RIOT) at Buy
-
Chardan Starts Keel Infrastructure (KEEL) at Buy
-
Chardan Downgrades Passage Bio Inc. (PASG) to Neutral
-
Allbirds secures $50 million convertible financing for AI pivot
-
Chardan Starts Healios KK (4593:JP) at Buy
-
Palvella Therapeutics (PVLA) PT Raised to $240 at Chardan
-
Form X-17A-5 CHARDAN CAPITAL MARKETS For: Dec 31
-
Chardan Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT) amid FDA accelerated approval
-
Corvex completes all-stock merger with Movano, raises $40.2 million
-
VivoPower converts 2.96 million shares to reduce public float
-
SAB Biotherapeutics prices $85 million public offering at $3.85 per share
-
Chardan Downgrades Urgent.ly (ULY) to Neutral
-
Chardan Reiterates Buy Rating on Orchestra BioMed Inc. (OBIO): "warrants a new look by investors"
-
uniQure BV (QURE) PT Raised to $31 at Chardan
-
EyePoint Inc. (EYPT) PT Raised to $29 at Chardan
-
Chardan Reiterates Buy Rating on Arbutus Biopharma (ABUS) Following Moderna Settlement
-
Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN)
-
Intellia Therapeutics (NTLA) PT Raised to $27 at Chardan
-
Chardan Capital Markets Upgrades Allurion Technologies (ALUR) to Buy
-
VivoPower terminates at-the-market equity offering agreement
-
Chardan Capital Markets Upgrades Korro Bio Inc. (KRRO) to Buy
-
Aldabra 4 completes $300.15 million IPO on NASDAQ
-
Aldabra 4 prices $261 million IPO at $10 per unit
-
Chardan Capital Markets Starts Alumis Inc (ALMS) at Buy
-
ZOOZ Reports Preliminary 2025 Financial Information, Cash and Bitcoin Positions and Additional Corporate Updates
-
Chardan Capital Markets Starts ZOOZ Strategy (ZOOZ) at Buy
-
Black Spade Acquisition III closes $172.5 million IPO on NYSE
-
Black Spade Acquisition III Co Announces Closing of $172.5 Million Initial Public Offering, Including Full-Exercise of Over-Allotment Option
-
Black Spade Acquisition III prices $150 million IPO
-
Black Spade Acquisition III Co Announces Pricing of $150 Million Initial Public Offering
-
Chardan Capital Markets Assumes Reviva Pharmaceuticals (RVPH) at Buy
-
Chardan Capital Markets Assumes Stoke Therapeutics (STOK) at Buy
-
Chardan Capital Markets Assumes Alto Neuroscience (ANRO) at Buy
-
QumulusAI files for direct listing on Nasdaq
-
Chardan Capital Markets Starts Hyperion DeFi, Inc. (HYPD) at Buy
-
Chardan Capital Markets Starts Hyperliquid Strategies, Inc. (PURR) at Buy
-
Chardan Capital Markets Starts Kalaris (KLRS) at Buy
-
Chardan Capital Markets Starts Annexon Biosciences (ANNX) at Buy
-
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
-
Palvella Therapeutics (PVLA) PT Raised to $174 at Chardan Capital Markets
-
Lion Group raises $10 million, allocates $8 million for bitcoin purchase
-
Lion Group Holding Ltd Announces $10 Million Private Placement for the acquisition of Bitcoin (BTC)
-
Hyperliquid Strategies completes business combination with Sonnet BioTherapeutics

